BioAge Labs Q2 NetLoss Expands; Expects QUELL-CV Phase 2 Results Of BGE-102 In H2 2026

BioAge Labs reported a wider net loss in Q2 even as collaboration-based revenue edged up. The results imply ongoing cost pressure for the clinical-stage company despite only a modest revenue improvement. Investors may view the update as cautious for near-term profitability.

Analysis

BioAge Labs reported a wider net loss in Q2 even as collaboration-based revenue edged up. The results imply ongoing cost pressure for the clinical-stage company despite only a modest revenue improvement. Investors may view the update as cautious for near-term profitability.